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While sirolimus (SRL) is thought to be a non-nephrotoxic
agent, cyclosporine A (CsA) toxicity is a serious problem in
kidney transplantation. We compared the effects of the two
drugs on T-helper (Th) subsets in kidney transplant patients.
We examined 24 first cadaver kidney recipients equally
randomized to receive SRL/mycophenolate mofetil (MMF)/
methylprednisolone (MP), or cyclosporine with either MMF or
MP. The Th1 and Th2 subsets in peripheral blood were
separated based on their production of interferon-c (INFc) or
interleukin (IL)-4/IL-5. The lymphocytes were stimulated with
phytohemoagglutinin or with allogenic CD3-depeted and
irradiated antigen-presenting cells. Furthermore, the
conversion potential of Th0 to Th1 was determined by
measuring IL-12 and IL-18 levels after lipopolysaccharide
challenge. When peripheral blood lymphocytes taken from
SRL-treated patients were stimulated by
phytohemoagglutinin, there were significantly lower
INFc-producing cells compared with the lymphocytes taken
from patients treated with CsA. The number of IL-4/IL-5-
producing cells did not differ among the patient groups.
Release of IL-12 but not IL-18 from peripheral lymphocytes
following treatment with lipopolysaccharide was significantly
lower in the SRL-treated patients. These results show that
compared with CsA, SRL caused a significant decrease in the
Th1 lymphocyte subset associated with a significant
reduction of IL-12 release.
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Acute and chronic cyclosporine A (CsA) nephrotoxicity are
still relevant clinical problems in kidney transplantation.1,2
Sirolimus (SRL) is a non-nephrotoxic agent that blocks signal
3 in the three-signal model of T cell-mediated rejection by
preventing cytokine receptors from activating the cell cycle.3,4
SRL immunosuppressive activity is mediated by the binding
to a unique serine-threonine kinase mammalian target of
rapamycin which plays a key role in cytokine-driven signals,
protein synthesis, and T-cell expansion via G1-S cell cycle
progression.5 T-cell proliferation under SRL immunosup-
pression is also inhibited by the block of the interleukin-2
(IL-2)-mediated signal-transduction.6
In the T cell-mediated rejection, T-helper (Th) lympho-
cytes play a critical role in either initiation and progression of
allograft rejection.7 CD4þ alloreactive response differen-
tiates into two distinct Th cell subsets, Th1 and Th2 cells,
characterized by distinct cytokine patterns.7,8 Th1 response is
defined by IL-2 and interferon-g (INFg) secretion, whereas
IL-4, IL-5, IL-6, and IL-13 are released by Th2 cells that
also promote B-cell maturation. The cytokine microenviron-
ment dictates whether a Th0 lymphocyte will develop
into a polarized Th1 or Th2 cell.7 Among other cytokines
secreted by monocyte and dendritic cells, IL-12 and IL-18
have a critical role in driving Th0 lymphocytes to Th1
polarization.8,9
Th1 cytokines have long been implicated in the acute
rejection process. In fact, a release of Th1 cytokines IL-2 and
IFNg has been reported in several gene expression studies in
experimental10 and human kidney transplantation at the
time of allograft rejection.11,12 Heeger et al.13 have demon-
strated that the number of pretransplant IFNg-producing
cells analyzed by an enzyme-linked immunosorbent spot
(ELISPOT) assay correlates with the risk of post-transplanta-
tion rejection episodes. Recent studies have established that
for measuring T-cell responses, the ELISPOT assay is more
sensitive than a number of other techniques like enzyme-
linked immunosorbent assay, intracellular cytokine staining,
or thymidine incorporation assays.14
In spite of the potential relevance of these issues, few data
are available on Th activity in immunosuppressed patients
after solid organ transplantation. The aim of the present study
was to compare Th subsets in kidney-transplanted patients
treated with SRL- or CsA-based immunosuppressive regimens.
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RESULTS
Patients enrolled into the study did not show signs of acute
rejection at the time of inclusion and never before
randomization. No severe bacterial, viral, or fungal infection
occurred before inclusion in the study. Plasma creatinine
levels were not significantly different in the rapamicine
(RAPA group) (1.2670.47 mg/dl) when compared with CsA-
1 (1.6670.52 mg/dl) and CsA-2 (1.5870.38 mg/dl) groups,
respectively. Side effects associated with immunosuppression
are summarized in Table 1. Hypertrygliceridemia and
hypercholesterolemia were a frequent finding in the RAPA
group (Table 1). SRL treatment was also associated with a
significant decrease of the platelet count. Liver enzymes levels
were similar in all groups. Arthralgia was only reported in
three patients (one male and two females) from the RAPA
group. Two cases of impaired glucose tolerance was found in
the CsA-1 and CsA-2 groups.
IFNc-producing cells
The number of unstimulated IFNg-producing cells was
similar in all groups (Figure 1). Number of phytohemagglu-
tin (PHA) stimulated IFNg-producing cells was significantly
lower in CsA-1 or CsA-2 groups (CsA-1: 129.6747.5 spots/
2 105 cells; CsA-2: 138.0727.8 spots/2 105 cells) when
compared with control (CON) group (488.1795.6 spots/
2 105 cells; Po0.01) and higher when compared with
RAPA patients (50.1713.8 spots/2 105 cells; Po0.05).
After allostimulation with antigen-presenting cells obtained
from peripheral blood mononuclear cells (PBMC, multiple
donors), IFNg-producing cells were still significantly lower in
RAPA group (Po0.05) when compared with both CsA
groups (Table 2).
IL-4-producing cells
As shown in Figure 2, the number of unstimulated IL-4-
producing cells was similar in all groups. After PHA
stimulation, all groups (CsA-1: 34.8712.2 spots/2 105
cells; CsA-2: 27.279.7 spots/2 105 cells; RAPA: 38.3710.6
spots/2 105 cells) showed a significantly lower number of
IL-4-producing cells when compared with the CON group
(86.0734.7 spots/2 105 cells; Po0.05).
IL-5-producing cells
The behavior of IL-5 replicates that of IL-4. Number of
unstimulated IL-5-producing cells was similar in all groups
(Figure 3). After PHA stimulation, all groups (CsA-1:
52.0714.3 spots/2 105 cells; CsA-2: 50.5711.8 spots/
2 105 cells; RAPA: 44.3710.6 spots/2 105 cells) showed
a significantly lower number of IL-5-producing cells when
compared with the CON group (133.6740.5 spots/2 105
cells; Po0.01). Similar results were obtained when IL-5-
producing cells were measured after allostimulation with
antigen-presenting cells (Table 2).
Th1/Th2 balance
IFNg-/IL-5-producing cell ratio is shown in Figure 3. Similar
results were observed in all groups of unstimulated cells.
After PHA stimulation, the IFNg-/IL-5-producing cell ratio
Table 1 | Immunosuppression side effects in all groups of
kidney-transplanted patients
RAPA (n=8) CsA-1 (n=8) CsA-2 (n=8)
n % n % n %
Hypertriglyceridemiaa 8 100 5 62.5 3 37.5
Hypercholesterolemiab 8 100 4 50 4 50
Hyperglycemiac 0 0 1 12.5 1 12.5
SGOT increased 1 12.5 1 12.5 3 37.5
SGPT increasee 1 12.5 2 25 3 37.5
Thrombocytopeniaf 3 37.5 0 0 0 0
Hypertensiong 5 62.5 3 37.5 6 75
Arthralgia 2 25 0 0 0 0
CsA, cyclosporine.
Levels obtained from early morning bleeding after overnight fasting:
aPlasma tryglicerides4150 mg/dl.
bPlasma cholesterol4220 mg/dl.
cPlasma glucose4110 mg/dl in at least two early morning measurements after
overnight fasting.
dSerum glutamic oxaloacetic transaminase (SGOT)439 mU/ml.
eSerum glutamic pyruvic transaminase (SGPT)434 mU/ml.
fPlatelet counto253 *103 l.
gBlood pressure4140/80 mm Hg in two consecutive measurements in at least two
clinical controls between month 2 and month 3 after transplantation.
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Figure 1 | Frequency of IFNc-producing cells. (a) Frequency of
IFNg-producing PBMC in cultures unstimulated (PHA) and
(b) stimulated (PHAþ ) of normal subjects (CON), and in recipients
of first cadaveric renal transplant. Patients were randomized in three
groups: RAPA were treated with SRL in association with MMF and
MP; CsA-1 with CsA and MMF; and CsA-2 with CsA, MMF, and MP.
*Po0.01 vs PHA-stimulated RAPA, CsA-1 and CsA-2 cells; **Po0.05 vs
PHA-stimulated CsA-1 and CsA-2 cells.
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was significantly lower in CsA-1 and CsA-2 groups when
compared to CON group (Po0.05), but significantly higher
(Po0.05) when compared with the RAPA group (Figure 4).
PBMC production of IL-12 and IL-18
Basal PBMC production of IL-12 was similar in all groups
(Figure 5). After lipopolysaccharide (LPS) stimulation, CsA-1
(159.6742.6 pg/2 106 PBMC) and CsA-2 (168.4754.7 pg/
2 106 PBMC) PBMC released less IL-12 than CON group
(486.07101.6 pg/2 106 PBMC; Po0.01 vs CsA-1 and vs
CsA-2) but more than RAPA group (77.3727.5 pg/2 106
PBMC; Po0.05 vs CsA-1 and vs CsA-2).
Similarly, constitutive synthesis of IL-18 by PBMC was not
significantly different among all groups (Figure 6). After LPS
stimulation, PBMC from CsA-1 (160.7746.3 pg/2 106
PBMC), CsA-2 (174.5757.2 pg/2 106 PBMC), and RAPA
(151.8758.3 pg/2 106 PBMC) patients released less IL-18
when compared with CON group (631.67215.0 pg/2 106
PBMC; Po0.01). No differences in IL-18 production were
also observed among CsA-1, CsA-2 and RAPA groups.
DISCUSSION
The Th1/Th2 paradigm has evolved as a unifying model to
explain the cytokine responses associated with T-cell activa-
tion in such different settings as autoimmune disease and
tolerance induction. Several studies indicate that a prevalence
of Th1 over Th2 characterizes renal allograft rejection,
Table 2 | Frequency of IFNc and IL-5-producing PBMC from first cadaveric kidney transplant recipients, in cultures of UN and
allostimulated with antigen-presenting cells (ST)
RAPA (n=6) CsA-1 (n=5) CsA-2 (n=5) CON (n=6)
IFNg UN (spots/2 105 cells) 3.672.4 5.172.5 3.272.7 2.771.8
IFNg ST (spots/2 105 cells) 32.8727.7*,1 68.3732.5* 76.5741.1* 233.57116.0
IL-5 UN (spots/2 105 cells) 6.974.0 6.074.3 7.275.5 7.276.2
IL-5 ST (spots/2 105 cells) 39.1717.6* 34.6720.8* 28.9716.0* 98.6759.3
IFNg, interferon-g; IL-5, interleukin-5; PBMC, peripheral blood mononuclear cells; UN, unstimulated; ST, stimulated.
RAPA were treated with SRL in association with MMF and MP; CsA-1 with CsA and MMF; and CsA-2 with CsA, MMF, and MP.
*Po0.05 vs CON; 1Po0.05 vs CsA-1 and CsA-2.
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Figure 2 | Frequency of IL-4-producing cells. (a) Frequency of
IL-4-producing PBMC in cultures unstimulated (PHA) and
(b) stimulated (PHAþ ) of normal subjects (CON), and in recipients of
first cadaveric renal transplant. Patients were randomized in three
groups: RAPA were treated with SRL in association with MMF and MP;
CsA-1 with CsA and MMF; and CsA-2 with CsA, MMF, and MP.
*Po0.05 vs PHA-stimulated RAPA, CsA-1 and CsA-2 cells.
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Figure 3 | Frequency of IL-5-producing cells. (a) Frequency of
IL-5-producing PBMC in cultures unstimulated (PHA) and
(b) stimulated (PHAþ ) of normal subjects (CON), and in recipients of
first cadaveric renal transplant. Patients were randomized in three
groups: RAPA were treated with SRL in association with MMF and MP;
CsA-1 with CsA and MMF; and CsA-2 with CsA, MMF, and MP.
*Po0.01 vs PHA-stimulated RAPA, CsA-1 and CsA-2 cells.
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whereas recruitment of Th2 is associated with graft
tolerance.15,16 These studies suggest that an effective
immunosuppressive treatment should be aimed to prevent
Th1 activation and maintain an equilibrated balance between
Th1 and Th2. As yet, the impact of different immunosup-
pressive regimens on Th1/Th2 balance has been poorly
investigated; in particular we ignore the effects of SRL, a drug
that has the major advantage, in comparison with calcineurin
inhibitors, of being not nephrotoxic.
Recently, ELISPOT assay has been proposed to study Th1/
Th2 balance in kidney-transplanted recipients.13,14 This
method allows the detection of cytokines secreted by single
cells within a polyclonal population allowing a detailed
analysis of lymphocyte populations secreting one or more
cytokines. Our data, based on ELISPOT analysis, showed that
both SRL- and CsA-based immunosuppressive regimens
induce a significant suppression of IFNg- and IL-5-producing
cells.
These results confirm that inhibition of Th1 is associated
with immunosuppressive treatment aimed to avoid graft
rejection,17,18 and are consistent with previous cell culture
studies showing inhibition of IFNg gene expression in the
presence of CsA and SRL.19,20 In a heart allograft rat study,
SRL also appeared to block significantly IFNg mRNA
expression.20 Our study shows that the number of IFNg-
producing cells is lower in patients on SRL- than in patients
under CsA-based regimens. These data are consistent with
previous animal studies showing that SRL immunosuppres-
sion can be 20–100 times more potent than CsA.18 To our
knowledge, the current literature lacks human studies on the
effectiveness of SRL on Th subsets. This is the first report
showing that SRL inhibition is more effective than CsA in
blocking Th1 recruitment in a setting where T cells are
activated, that is, reproducing acute rejection.
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Figure 4 | IFNc/IL-5 (Th1/Th2) ratio of normal subjects (CON), and
in recipients of first cadaveric renal transplant. Patients were
randomized in three groups: RAPA were treated with SRL in
association with MMF and MP; CsA-1 with CsA and MMF; and CsA-2
with CsA, MMF, and MP. SRL, sirolimus; MMF, mycophenolate mofetil;
CsA, cyclosporine; *indicates a significant difference between
stimulated (PHAþ ) and unstimulated (PHA) cells of the same
group (Po0.02 CON, Po0.03 CsA-1 and CsA-2; Po0.05 RAPA);
1indicates a significant difference between CON-stimulated (PHAþ )
cells vs RAPA (Po0.01), and vs CsA-1 and CsA-2 (Po0.05); 11Po0.05
vs PHA-stimulated CsA-1 and CsA-2 cells.
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Figure 5 | IL-12 production by PBMC. (a) IL-12 production of
PBMC in cultures unstimulated (LPS-) and (b) stimulated (LPSþ ) of
normal subjects (CON), and in recipients of first cadaveric renal
transplant. Patients were randomized in three groups: RAPA were
treated with SRL in association with MMF and MP; CsA-1 with CsA
and MMF; and CsA-2 with CsA, MMF, and MP. *Po0.01 vs LPS-
stimulated cells of all patients. **Po0.05 vs LPS-stimulated CsA-1 and
CsA-2.
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Figure 6 | IL-18 production by PBMC. (a) IL-18 production by
PBMC in cultures unstimulated (LPS) and (b) stimulated (LPSþ ) of
normal subjects (CON), and in recipients of first cadaveric renal
transplant. Patients were randomized in three groups: RAPA were
treated with SRL in association with MMF and MP; CsA-1 with CsA
and MMF; and CsA-2 with CsA, MMF, and MP. *Po0.01 vs LPS-
stimulated cells from all groups.
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Th2 response measured as number of IL-4- and IL-5-
positive cells of PHA or allostimulated PBMC collected from
grafted patients was inhibited when compared with normal
controls but did not show differences when compared with
SRL- or CsA-based immunosuppression. A previous mRNA
expression study on human PBMC from normal individuals
also showed that either SLR or CsA suppress both IL-4- and
IL-5 expression elicited by PHA.21 Our report shows that SRL
inhibition on IFNg is significantly more effective than CsA
suggesting a better Th1 blockade in kidney-transplanted
patients.
In our work, LPS-stimulated PBMC collected from RAPA
patients released less IL-12, but similar amounts of IL-18,
when compared with PBMC from both CsA groups. It
suggests that IL-12 and IL-18 could differentially amplify
CD4þ T cell production of IFNg. In a previous study,
murine carcinoma cells expressing mIL-12 or mIL-18
appeared to be less tumorigenic than control cells and that
the antitumor effect required IFNg22 suggesting a synergistic
effect of IL-12 and IL-18 in inducing Th1 polarization of
CD4þ T cells. However, data by Takeda et al.23 showed that
splenic T cells from IL-12/ mice did not differentiate into
IFNg-producing Th1 cells by in vitro stimulation with IL-18,
although in vitro stimulation with IL-12 induced almost
normal Th1 cell development in IL-18/ mice. Robinson
et al.24 showed that IFNg-inducing factor cannot replace IL-
12 but synergizes with IL-12 for IFNg production. Moreover,
Seder et al.25 demonstrated that IL-12 acts directly on CD4þ
T cells enhancing their ability to develop into IFNg-
producing cells. These data suggest that IL-12, but not
IL-18, could be a relevant cytokine in the CD4þ micro-
environment to polarizing T cells toward the Th1 phenotype.
Downregulation of Th1 cytokine release that we observed
in the RAPA group can then be explained not only with a
significant monocyte production of IL-12, but also by
immature SRL-treated dendritic cells (SRL-DC) migration
to lymphoid tissues. SRL-DC inhibit IFNg T-cell production
promoting Th2 polarization. In vitro and in vivo data by
Sordi et al.26 demonstrated an increased surface expression of
chemokine receptors and lymphoid migratory activity of
human and mouse SRL-DC. CsA and tacrolimus instead did
not activate either chemokine receptors expression and
lymph node migration.26 Mouse-derived SRL-DC showed
reduced IFNg production associated to Janus kinase 2/signal
transducer and activator of transcription 4 and their
administration significantly prolonged survival of mouse
cardiac allografts.27 Monti et al.28 found a dose-dependent
reduction of IFNg in T cells after SRL-DC stimulation.
Finally, Tao et al.29 described how SRL-DC are resistant to
maturation influencing immune reactivity and tolerance
induction through downregulation of T-cell alloreactivity.
When peripheral tolerance to allogenic organ grafts
occurs, CD4þ T cells appear to develop the capacity of
inducing tolerance in further cohort of T cells. This
mechanism of ‘infectious tolerance’, maintained by a Th2
polarization or even by a Th2-like activation, is a recent
attractive explanation for allogeneic organ transplantation
tolerance.7,15,30 Several in vivo studies on cytokine expression
during tolerance induction have consistently shown a
dramatic decrease of IL-2 and IFNg expression30 encouraging
the hypothesis that polarization toward Th2 might improve
graft survival. Our report shows that SRL-based immuno-
suppression lowering Th1/Th2 ratio results in a more
effective Th2 polarization of CD4þ T cells when compared
to CsA-based immunosuppression in kidney-transplanted
patients.
Recent works have elucidated clearly the effects of SRL on
CD4þCD25þ T cells (Treg).31–33 Treg cultured in the
presence of SRL, but not CsA, preserve the dominance of
highly suppressive CD27þ Treg subset after allogeneic
expansion of CD4þCD25þ T cells in vitro.31 TCR, CD28,
or IL-2 expansion of CD4þCD25þ T cells is resistant to
SRL-induced apoptosis and after SRL culture they constitu-
tively express Foxp3.32 CD4þCD25þFoxp3þ T cells sup-
press proliferation and effector function of CD4þCD8þ T
cells in vitro.32 Activation of human CD4þ T cells from
healthy individuals in the presence SRL lead to the growth of
CD4þCD25þFoxp3þ T cells and to selective depletion of
CD4þCD25 effector cells.33
In summary, our findings suggest a sequence of events
beginning with inhibition of monocyte activation associated
with low release of IL-12. The significantly lower release of
IL-12 in patients on SRL-based immunosuppression and
SRL-DC-induced T-cell alloreactivity could explain the
reduced IFNg-/IL-5-producing cell ratio eventually resulting
in a prevalence of Th2 cells in these patients. The present
understanding of acute and chronic allograft rejection has
identified a cell-mediated mechanism where CD4þ Th1 cells
play a central role, whereas modulation of Th2 response
might improve host tolerance7,8,34 and eventually late graft
survival. Whether long-term management with SRL im-
proves long-term graft survival reducing the toxic effects of
calcineurin inhibition together with a more effective
Th1 inhibition should be evaluated in future prospective
studies.
MATERIALS AND METHODS
Study design
The study was conducted in accordance with the Declaration of
Helsinki, and all patients provided written informed consent.
Twenty-four recipients of first cadaveric kidney transplant (13
males and 11 females) were enrolled into the study. At the time of
transplant, operation patients were randomly assigned to one of the
three immunosuppressive regimens: (1) RAPA group: SRL and
mycophenolate mofetil (MMF); (2) CsA-1 group: CsA and MMF;
and (3) CsA-2 group: CsA and methylprednisolone (MP). To study
clinically stable patients, they were included into the study at third
month after kidney transplantation. Blood was always collected
from patients just before the assumption of immunosuppressive
therapy and after overnight fasting. Within the month previous
enrolment and at the time of bleeding, all transplanted patients did
not present laboratory or clinical signs of both infection and acute
rejection.
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Unstimulated and PHA-stimulated T-cell polarization was
analyzed measuring IFNg, IL-4, and IL-5-secreting PBMC detected
by an ELISPOT assay. The number of IL-5- and IFNg-producing
cells of patients and CON group was also measured after
allostimulation as we described in a previous paper.35 In brief,
PBMC were isolated from the buffy coat of 10 healthy volunteer
donors (Trasfusion Center, Fondazione IRCCS Policlinico San
Matteo, Pavia, Italy). Leukocyte-rich buffy coat cells were centri-
fuged over Ficoll-Hypaque layers to collect PBMC. CD3þ T cells
were depleted by negative selection with anti-CD3 magnetic
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). PBMC
CD3þ depleted were irradiated at 30 Gy using a g-radiation source,
and cocultured with equal numbers of PBMC from kidney-
transplanted patients and CON.
IL-12 and IL-18 levels were analyzed in cell-free supernatants
obtained from unstimulated and stimulated PBMC.
Intraindividual variability was analyzed in a preliminary study
performed on six-transplanted patients and three healthy volunteers.
Blood samples were collected in three consecutive days for both
ELISPOT and cytokine analysis on cell-free supernatants. Within-
subject ELISPOT variability for both renal-transplanted patients and
volunteers was always less than 27, 32, and 30% for IFNg, IL-4, and
IL-5, respectively. To avoid the wide citokine variability usually
observed on plasma samples,36 IL-12 and IL-18 levels were analyzed
on cell-free supernatants of PBMC cultures. Within-subject
variability for both renal-transplanted patients and healthy volun-
teers for IL-12 and IL-18 was always less than 25 and 33%,
respectively.
Patients
RAPA group: Eight patients (three males and five females) aged
46.2712.3 years were treated with SRL in association with MMF
(22.975.5 mg/kg/day) and MP (8 mg/day all patients). CsA-1
group: Eight patients (four males and four females) aged
45.879.6 years (P¼NS vs RAPA) were treated with CsA and
MMF (21.777.5 mg/kg/day; P¼NS vs RAPA). CsA-2 group: Eight
patients (six males and two females) aged 44.2711.5 years (P¼NS
vs RAPA and vs CsA-2) treated with CsA, MMF (20.076.6 mg/kg/
day; P¼NS vs CsA-1), and MP (16 mg/day all patients). Patients
treated with SRL received an oral loading dose of 3.5 mg/m2/day for
2 days, followed by 2.5 mg/m2/day, then adjusted to achieve steady-
state whole-blood trough levels of approximately 12–16 ng/ml
(Table 3). Patients treated with CsA received an initial oral dose
of 8 mg/kg/day then adjusted to maintain whole-blood trough levels
of 200–300 ng/ml for 2 months, and 200–250 ng/ml thereafter
(Table 3). None of the enrolled patients was under treatment with
drugs known as immunomodulators, such as statins, calcitriol, and
angiotensin-converting enzyme inhibitors, after kidney transplanta-
tion. Blood samples were also collected from eight healthy
volunteers (CON) aged 38.4710.6 years (four males and four
females; P¼NS vs all transplanted groups).
Trough-level determinations
Whole-blood SRL levels was monitored using high-performance
liquid chromatography (HPLC) with ultraviolet detection.37 Whole-
blood CsA was detected using a monoclonal technique (Abbott
TDX, Diamond Diagnostics, Holliston, MA, USA). Plasma total
mycophenolic acid levels were measured by reversed-phase high-
performance liquid chromatography.
Cell separation
PBMC were isolated from peripheral blood by standard Ficoll
density-gradient centrifugation and were either used immediately or
frozen for later use.38 Average PBMC lymphocytes and monocytes
removed was 77% (range 75–80) and 23% (range 20–25),
respectively. Average PBMC lymphocyte fractions harvested from
RAPA, CsA-1, and CsA-2 groups were similar among the three
groups 79, 77, and 76%, respectively. PBMC viability determined by
tryptan blue dye exclusion test was always greater than 95%.
PBMC cultures
PBMC were resuspended at a cell density of 2 106 cells/ml in
Rosewell Park Memorial Institute 1640 medium (Invitrogen,
Carlsbad, CA, USA) containing 1% decomplementated fetal calf
serum inactivated at 561C (Sigma-Aldrich, St Louis, MO, USA) in
humidified atmosphere containing 5% CO2, 2 mM L-glutamine,
100 IU/ml penicillin, and 100 g/ml streptomycin (Sigma-Aldrich).
Unstimulated or tested against LPS (10 mg/ml; Sigma-Aldrich,
Milan, Italy) PBMC were cultured for 24 h and analyzed. Cell-free
supernatants were collected by centrifugation for 10 min at
400 r.p.m., passed through a millipore filter (0.2 m, Sigma-Aldrich)
and stored at 801C.39
ELISPOT assay
Th1 and Th2 cell function was evaluated by measuring PBMC
production of IFNg and IL-5 by the ELISPOT assay as described
previously.40 Briefly, 96-well plates (Polyfiltronics, Rockland, MA,
USA) were coated with 100ml capture monoclonal antibodies
(MoAb) specific for IFNg (clone 2G1, 5 mg/ml, Endogen, Woburn,
MA, USA) or IL-5 (clone 5A10, 8 mg/ml, Endogen) in phosphate-
buffered saline (PBS) overnight at 41C. Plates were washed and
blocked for 2 h at room temperature in 10% fetal calf serum
phosphate-buffered saline, then 3 105 PBMC were resuspended in
100 ml Rosewell Park Memorial Institute medium. Unstimulated,
PHA stimulated (15 ml/ml), or antigen-presenting cells allostimu-
lated plates were incubated for 48 h at 371C, washed and wells
coated with 100ml IFNg MoAb (clone B133.5 1 mg/ml, Endogen)
and IL-5 MoAb (clone 39D10, 2 mg/ml, Endogen) for 2 h at 371C.
After washing, all wells were coated with 100 ml of HRP-conjugated
streptavidin (Endogen), incubated for 30 min, washed again and
developed using a 3-amino-9-ethylcarbazole (Sigma-Aldrich) fil-
tered solution obtained diluting 1 mg into 30 ml of 0.1 mol/l sodium
acetate buffer mixed with 15 ml H2O2.
IL-4 were measured by commercial ELISPOT assay (Quantikine,
R&D System, Minneapolis, MN, USA) performed on microtiter
plate.
Spots were counted with an automated ELISA-Spot Assay Video
Analysis System (A-EL-VIS, Hannover, Germany). Results were
expressed as number of spots/2 105 seeded cells.
Table 3 | Through levels of SRL, CsA, and MMF
RAPA (n=8) CsA-1 (n=8) CsA-2 (n=8)
SRL (ng/ml) 12.774.4 n/a n/a
CsA (ng/ml) n/a 221739 262746
MMF (ng/ml) 2.971.6 2.170.7 3.271.8
CsA, cyclosporine A; MMF, mycophenolate mofetil; n/a, not applicable;
SRL, sirolimus.
Levels obtained from early morning bleeding after overnight fasting and just before
administration of immunosuppression therapy.
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Cytokine assays
Cytokines (IL-12 p70 and IL-18) were assessed by enzyme-linked
immunosorbent assay on cell-free supernatant. Antibody pairs were
used according to instructions of the supplier firms. IL-18 assay was
performed with reagents obtained from R&D System (Minneapolis)
(primary, MoAb: clone 52713.11, 1 mg/ml; secondary, PolyAb
250 ng/ml); assay sensitivity was 4.3 pg/ml. Bioactive p70 IL-12
assay were performed with reagents supplied by Endogen as follows:
IL-12 MoAb clone 20C2 at 4 mg/ml, detecting MoAb clone C8.6 at
1 mg/ml (assay sensitivity 2.5 pg/ml).
Statistics
Data are expressed as mean7s.d. Statistical analysis was performed
using analysis of variance (ANOVA) for repeated measures and the
Bonferroni’s multiple comparisons test. Correlation analyses were
performed by STATVIEW software for MacIntosh. The null
hypothesis was rejected when the Po0.05.
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